Literature DB >> 19143562

Selection of HIV variants with signature genotypic characteristics during heterosexual transmission.

Manish Sagar1, Oliver Laeyendecker, Sandra Lee, Jordyn Gamiel, Maria J Wawer, Ronald H Gray, David Serwadda, Nelson K Sewankambo, James C Shepherd, Jonathan Toma, Wei Huang, Thomas C Quinn.   

Abstract

BACKGROUND: Newly infected subjects acquire a limited number of human immunodeficiency virus type 1 (HIV-1) variants with specific genotypic and phenotypic features from the array of viruses present in a chronically infected transmitting partner.
METHODS: We examined HIV-1 envelope sequences from the earliest available serum sample after HIV-1 acquisition in 13 newly infected subjects and from their epidemiologically linked HIV-1-infected heterosexual partner. Samples from both members were collected on the same day in the Rakai Community Cohort Study.
RESULTS: Ten couples were infected with subtype D HIV-1, and 3 pairs had subtype A HIV-1. Newly infected subjects acquired a subset of the viruses that were circulating in the transmitting partner; transmitted variants had less diversity and divergence and were more closely related to the ancestral sequences. The majority of signature amino acid differences among donor and recipient sequences were in and immediately following the V3 loop. Envelopes from recipients were significantly shorter and had a lower V3 charge than envelopes from donors, but there was no significant difference in the number of potential N-linked glycosylation sites.
CONCLUSION: A minority subset of HIV-1 variants with signature genotypes is favored for transmission in this population.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19143562      PMCID: PMC2755256          DOI: 10.1086/596557

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  41 in total

1.  HIV-1 genomic RNA diversification following sexual and parenteral virus transmission.

Authors:  T F Wolfs; G Zwart; M Bakker; J Goudsmit
Journal:  Virology       Date:  1992-07       Impact factor: 3.616

2.  Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution.

Authors:  J J De Jong; A De Ronde; W Keulen; M Tersmette; J Goudsmit
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

3.  Detecting isolation by distance using phylogenies of genes.

Authors:  M Slatkin; W P Maddison
Journal:  Genetics       Date:  1990-09       Impact factor: 4.562

4.  A randomized, community trial of intensive sexually transmitted disease control for AIDS prevention, Rakai, Uganda.

Authors:  M J Wawer; R H Gray; N K Sewankambo; D Serwadda; L Paxton; S Berkley; D McNairn; F Wabwire-Mangen; C Li; F Nalugoda; N Kiwanuka; T Lutalo; R Brookmeyer; R Kelly; T C Quinn
Journal:  AIDS       Date:  1998-07-09       Impact factor: 4.177

5.  Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection.

Authors:  R Liu; W A Paxton; S Choe; D Ceradini; S R Martin; R Horuk; M E MacDonald; H Stuhlmann; R A Koup; N R Landau
Journal:  Cell       Date:  1996-08-09       Impact factor: 41.582

6.  In vivo sequence variability of human immunodeficiency virus type 1 envelope gp120: association of V2 extension with slow disease progression.

Authors:  T Shioda; S Oka; X Xin; H Liu; R Harukuni; A Kurotani; M Fukushima; M K Hasan; T Shiino; Y Takebe; A Iwamoto; Y Nagai
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

7.  Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule.

Authors:  R A Fouchier; M Groenink; N A Kootstra; M Tersmette; H G Huisman; F Miedema; H Schuitemaker
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

8.  Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants.

Authors:  S M Wolinsky; C M Wike; B T Korber; C Hutto; W P Parks; L L Rosenblum; K J Kunstman; M R Furtado; J L Muñoz
Journal:  Science       Date:  1992-02-28       Impact factor: 47.728

9.  Relationship of human immunodeficiency virus type 1 sequence heterogeneity to stage of disease.

Authors:  T McNearney; Z Hornickova; R Markham; A Birdwell; M Arens; A Saah; L Ratner
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

10.  Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study.

Authors:  M Dean; M Carrington; C Winkler; G A Huttley; M W Smith; R Allikmets; J J Goedert; S P Buchbinder; E Vittinghoff; E Gomperts; S Donfield; D Vlahov; R Kaslow; A Saah; C Rinaldo; R Detels; S J O'Brien
Journal:  Science       Date:  1996-09-27       Impact factor: 47.728

View more
  76 in total

1.  Biomarkers of HIV-1-associated neurocognitive disorders: challenges of proteomic approaches.

Authors:  Pawel Ciborowski
Journal:  Biomark Med       Date:  2009-12       Impact factor: 2.851

2.  Recombination-mediated changes in coreceptor usage confer an augmented pathogenic phenotype in a nonhuman primate model of HIV-1-induced AIDS.

Authors:  Yoshiaki Nishimura; Masashi Shingai; Wendy R Lee; Reza Sadjadpour; Olivia K Donau; Ronald Willey; Jason M Brenchley; Ranjini Iyengar; Alicia Buckler-White; Tatsuhiko Igarashi; Malcolm A Martin
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

3.  Sensitivity to Broadly Neutralizing Antibodies of Recently Transmitted HIV-1 Clade CRF02_AG Viruses with a Focus on Evolution over Time.

Authors:  Karl Stefic; Mélanie Bouvin-Pley; Asma Essat; Clara Visdeloup; Alain Moreau; Cécile Goujard; Marie-Laure Chaix; Martine Braibant; Laurence Meyer; Francis Barin
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

Review 4.  Targeting Trojan Horse leukocytes for HIV prevention.

Authors:  Deborah J Anderson; Joseph A Politch; Adam M Nadolski; Caitlin D Blaskewicz; Jeffrey Pudney; Kenneth H Mayer
Journal:  AIDS       Date:  2010-01-16       Impact factor: 4.177

5.  Evolution of the Envelope Glycoprotein of HIV-1 Clade B toward Higher Infectious Properties over the Course of the Epidemic.

Authors:  Laurence Meyer; Francis Barin; Mélanie Bouvin-Pley; Maxime Beretta; Alain Moreau; Emmanuelle Roch; Asma Essat; Cécile Goujard; Marie-Laure Chaix; Nathalie Moiré; Loïc Martin; Martine Braibant
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

Review 6.  Barriers to mucosal transmission of immunodeficiency viruses.

Authors:  Brandon F Keele; Jacob D Estes
Journal:  Blood       Date:  2011-05-09       Impact factor: 22.113

7.  Novel HIV vaccine strategies: overview and perspective.

Authors:  Yehuda Z Cohen; Raphael Dolin
Journal:  Ther Adv Vaccines       Date:  2013-09

8.  The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.

Authors:  Nicos Karasavvas; Erik Billings; Mangala Rao; Constance Williams; Susan Zolla-Pazner; Robert T Bailer; Richard A Koup; Sirinan Madnote; Duangnapa Arworn; Xiaoying Shen; Georgia D Tomaras; Jeffrey R Currier; Mike Jiang; Craig Magaret; Charla Andrews; Raphael Gottardo; Peter Gilbert; Timothy J Cardozo; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Punnee Pitisuttithum; Jaranit Kaewkungwal; Robert Paris; Kelli Greene; Hongmei Gao; Sanjay Gurunathan; Jim Tartaglia; Faruk Sinangil; Bette T Korber; David C Montefiori; John R Mascola; Merlin L Robb; Barton F Haynes; Viseth Ngauy; Nelson L Michael; Jerome H Kim; Mark S de Souza
Journal:  AIDS Res Hum Retroviruses       Date:  2012-10-04       Impact factor: 2.205

Review 9.  Rectal microbicide development.

Authors:  Ian McGowan; Charlene Dezzutti
Journal:  Curr Top Microbiol Immunol       Date:  2014       Impact factor: 4.291

10.  Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design.

Authors:  Li-Hua Ping; Sarah B Joseph; Jeffrey A Anderson; Melissa-Rose Abrahams; Jesus F Salazar-Gonzalez; Laura P Kincer; Florette K Treurnicht; Leslie Arney; Suany Ojeda; Ming Zhang; Jessica Keys; E Lake Potter; Haitao Chu; Penny Moore; Maria G Salazar; Shilpa Iyer; Cassandra Jabara; Jennifer Kirchherr; Clement Mapanje; Nobubelo Ngandu; Cathal Seoighe; Irving Hoffman; Feng Gao; Yuyang Tang; Celia Labranche; Benhur Lee; Andrew Saville; Marion Vermeulen; Susan Fiscus; Lynn Morris; Salim Abdool Karim; Barton F Haynes; George M Shaw; Bette T Korber; Beatrice H Hahn; Myron S Cohen; David Montefiori; Carolyn Williamson; Ronald Swanstrom
Journal:  J Virol       Date:  2013-04-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.